KIT is also a well-established therapeutic target in gastrointestinal stromal tumors (GIST), where activating mutations drive disease pathogenesis and predict robust responses to tyrosine kinase inhibitors (TKI) such as imatinib [8,9]. Here, KIT is linked to gastrointestinal stromal tumor.